AAPL 206.98 +2.37 (+1.16%)MSFT 124.94 +1.19 (+0.96%)FB 183.46 +1.67 (+0.92%)ZNGA 5.62 +0.1 (+1.81%)NVDA 191.36 +2.88 (+1.53%)WBA 53.72 -0.38 (-0.69%)GOOG 1266.32 +17.6 (+1.41%)PIH 5.25 -0.05 (-0.94%)
AAPL 206.98 +2.37 (+1.16%)MSFT 124.94 +1.19 (+0.96%)FB 183.46 +1.67 (+0.92%)ZNGA 5.62 +0.1 (+1.81%)NVDA 191.36 +2.88 (+1.53%)WBA 53.72 -0.38 (-0.69%)GOOG 1266.32 +17.6 (+1.41%)PIH 5.25 -0.05 (-0.94%)

Cash Flow APLS Quote Apellis Pha

All | Income Statement | Balance Sheet | Cash Flow | Retained Earnings | PPE Schedule | Intangible and Goodwill Schedule
Year 201420152016
NetIncome -27 -51 -128
Depreciation 0 0 0
DeferredIncomeT 0 0 0
StockBasedCompe 1 5 8
AccountsReceiva 0 0 0
InventoryCS 0 0 0
AccountsPayable 0 1 7
OtherWorkingCap 0 0 -2
OtherNonCashIte 0 0 1
NetCashProvided -26 -47 -131
InvestmentsInPP 0 0 0
AcquisitionsNet 0 0 0
PurchasesOfInve 0 0 0
SalesMaturities 0 0 0
PurchasesOfInta 0 0 0
OtherInvestingA 0 0 0
NetCashUsedForI 0 0 0
DebtIssued 0 26 0
DebtRepayment 0 0 0
CommonStockIssu 0 151 131
CommonStockRepu 0 0 0
DividendPaid 0 0 0
OtherFinancingA 0 1 1
NetCashProvided 15 197 132
NetChangeInCash -11 151 1
CashAtBeginning 36 25 176
CashAtEndOfPeri 25 176 176
Apellis Pharmaceuticals Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Apellis Pharmaceuticals Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.